Identification of Mycobacterium tuberculosis Clinical Isolates with Altered Phagocytosis by Human Macrophages Due to a Truncated Lipoarabinomannan*

Phenotypically distinct clinical isolates of Mycobacterium tuberculosis are capable of altering the balance that exists between the pathogen and human host and ultimately the outcome of infection. This study has identified two M. tuberculosis strains (i.e. HN885 and HN1554) among a bank of clinical isolates with a striking defect in phagocytosis by primary human macrophages when compared with strain Erdman, a commonly used laboratory strain for studies of pathogenesis. Mass spectrometry in conjunction with NMR studies unequivocally confirmed that both HN885 and HN1554 contain truncated and more branched forms of mannose-capped lipoarabinomannan (ManLAM) with a marked reduction of their linear arabinan (corresponding mainly to the inner Araf-α(1→5)-Araf unit) and mannan (with fewer 6-Manp residues and more substitutions in the linear Manp-α(1→6)-Manp unit) domains. The truncation in the ManLAM molecules produced by strains HN885 and HN1554 led to a significant reduction in their surface availability. In addition, there was a marked reduction of higher order phosphatidyl-myo-inositol mannosides and the presence of dimycocerosates, triglycerides, and phenolic glycolipid in their cell envelope. Less exposed ManLAM and reduced higher order phosphatidyl-myo-inositol mannosides in strains HN885 and HN1554 resulted in their low association with the macrophage mannose receptor. Despite reduced phagocytosis, ingested bacilli replicated at a fast rate following serum opsonization. Our results provide evidence that the clinical spectrum of tuberculosis may be dictated not only by the host but also by the amounts and ratios of surface exposed mycobacterial adherence factors defined by strain genotype.

[1]  K. Khoo,et al.  The Identification and Location of Succinyl Residues and the Characterization of the Interior Arabinan Region Allow for a Model of the Complete Primary Structure of Mycobacterium tuberculosis Mycolyl Arabinogalactan* , 2008, Journal of Biological Chemistry.

[2]  S. Kaufmann,et al.  Handbook of Tuberculosis , 2008 .

[3]  Peter M. Small,et al.  The W-Beijing Lineage of Mycobacterium tuberculosis Overproduces Triglycerides and Has the DosR Dormancy Regulon Constitutively Upregulated , 2007, Journal of bacteriology.

[4]  A. Azad,et al.  Fine Discrimination in the Recognition of Individual Species of Phosphatidyl-myo-Inositol Mannosides from Mycobacterium tuberculosis by C-Type Lectin Pattern Recognition Receptors1 , 2006, The Journal of Immunology.

[5]  J. Goldberg,et al.  Overexpression of Mycobacterium tuberculosis manB, a phosphomannomutase that increases phosphatidylinositol mannoside biosynthesis in Mycobacterium smegmatis and mycobacterial association with human macrophages , 2005, Molecular microbiology.

[6]  A. Azad,et al.  The human macrophage mannose receptor directs Mycobacterium tuberculosis lipoarabinomannan-mediated phagosome biogenesis , 2005, The Journal of experimental medicine.

[7]  J. Belisle,et al.  Export-Mediated Assembly of Mycobacterial Glycoproteins Parallels Eukaryotic Pathways , 2005, Science.

[8]  P. Brennan,et al.  Roles of Conserved Proline and Glycosyltransferase Motifs of EmbC in Biosynthesis of Lipoarabinomannan* , 2005, Journal of Biological Chemistry.

[9]  K. Khoo,et al.  Truncated Structural Variants of Lipoarabinomannan in Mycobacterium leprae and an Ethambutol-resistant Strain of Mycobacterium tuberculosis* , 2004, Journal of Biological Chemistry.

[10]  M. Reed,et al.  A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response , 2004, Nature.

[11]  S. Homans,et al.  Identification of the 5-methylthiopentosyl substituent in Mycobacterium tuberculosis lipoarabinomannan. , 2004, Angewandte Chemie.

[12]  G. Besra,et al.  Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response , 2004, Molecular microbiology.

[13]  P. Brennan,et al.  Characterization of the epitope of anti-lipoarabinomannan antibodies as the terminal hexaarabinofuranosyl motif of mycobacterial arabinans. , 2002, Microbiology.

[14]  G. Kaplan,et al.  Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-α/β , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Kay-Hooi Khoo,et al.  Variation in Mannose-capped Terminal Arabinan Motifs of Lipoarabinomannans from Clinical Isolates of Mycobacterium tuberculosis and Mycobacterium avium Complex* , 2001, The Journal of Biological Chemistry.

[16]  B. Britigan,et al.  Gallium Disrupts Iron Metabolism of Mycobacteria Residing within Human Macrophages , 2000, Infection and Immunity.

[17]  William R. Jacobs,et al.  Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice , 1999, Nature.

[18]  G. Puzo,et al.  Structural definition of arabinomannans from Mycobacterium bovis BCG , 1999, Glycoconjugate Journal.

[19]  P. Haslett,et al.  Mycobacterium tuberculosis CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates. , 1999, Journal of immunology.

[20]  I. Onorato,et al.  An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis. , 1998, The New England journal of medicine.

[21]  K. Khoo,et al.  Mycobacterial lipoarabinomannan: an extraordinary lipoheteroglycan with profound physiological effects. , 1998, Glycobiology.

[22]  K. Khoo,et al.  Galactosamine in walls of slow-growing mycobacteria. , 1997, The Biochemical journal.

[23]  T. Whittam,et al.  Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[24]  S. Iyer,et al.  Differences in mannose receptor-mediated uptake of lipoarabinomannan from virulent and attenuated strains of Mycobacterium tuberculosis by human macrophages. , 1996, Journal of immunology.

[25]  D. Rouse,et al.  Site‐directed mutagenesis of the katG gene of Mycobacterium tuberculosis: effects on catalase–peroxidase activities and isoniazid resistance , 1996, Molecular microbiology.

[26]  J. Musser,et al.  Identification of a polymorphic nucleotide in oxyR specific for Mycobacterium bovis , 1996, Journal of clinical microbiology.

[27]  K. Khoo,et al.  Structural definition of acylated phosphatidylinositol mannosides from Mycobacterium tuberculosis: definition of a common anchor for lipomannan and lipoarabinomannan. , 1995, Glycobiology.

[28]  L. Schlesinger,et al.  Binding of the terminal mannosyl units of lipoarabinomannan from a virulent strain of Mycobacterium tuberculosis to human macrophages. , 1994, Journal of immunology.

[29]  A. Telenti,et al.  Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations , 1994, Antimicrobial Agents and Chemotherapy.

[30]  P. Brennan,et al.  Enzymatic evidence for the presence of a critical terminal hexa-arabinoside in the cell walls of Mycobacterium tuberculosis. , 1994, Glycobiology.

[31]  P. Brennan,et al.  Structure and antigenicity of lipoarabinomannan from Mycobacterium bovis BCG. , 1993, Journal of general microbiology.

[32]  P. Chaurand,et al.  Structural features of lipoarabinomannan from Mycobacterium bovis BCG. Determination of molecular mass by laser desorption mass spectrometry. , 1993, The Journal of biological chemistry.

[33]  L. Schlesinger Macrophage phagocytosis of virulent but not attenuated strains of Mycobacterium tuberculosis is mediated by mannose receptors in addition to complement receptors. , 1993, Journal of immunology.

[34]  P. Brennan,et al.  Lipoarabinomannan of Mycobacterium tuberculosis. Capping with mannosyl residues in some strains. , 1992, The Journal of biological chemistry.

[35]  P. Brennan,et al.  Lipoarabinomannan. Multiglycosylated form of the mycobacterial mannosylphosphatidylinositols. , 1992, The Journal of biological chemistry.

[36]  P. Brennan,et al.  Structural features of the arabinan component of the lipoarabinomannan of Mycobacterium tuberculosis. , 1991, The Journal of biological chemistry.

[37]  M. Horwitz,et al.  Phagocytosis of Mycobacterium tuberculosis is mediated by human monocyte complement receptors and complement component C3. , 1990, Journal of immunology.

[38]  P. Stahl,et al.  Identification of the macrophage mannose receptor as a 175-kDa membrane protein. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[39]  F. Smith,et al.  A Colorimetric Method for the Determination of Sugars , 1951, Nature.

[40]  Stewart T. Cole,et al.  Tuberculosis and the tubercle bacillus. , 2005 .

[41]  S. Gordon,et al.  Binding properties of the mannose receptor. , 2001, Immunobiology.

[42]  M. Rivière,et al.  Comparative structural study of the mannosylated-lipoarabinomannans from Mycobacterium bovis BCG vaccine strains: characterization and localization of succinates. , 1997, Glycobiology.